MOLECULAR PARTNERS AG Stock Price, News & Analysis

Molecular Partners (MOLN) reported its Q4 2024 and full-year financial results, highlighting significant progress in its DARPin therapeutics pipeline. The company ended 2024 with CHF 149.4 million in cash and equivalents, expected to support operations into 2027.

Key developments include:

• Radio-DARPin MP0712 targeting DLL3 to enter first human trials in 2025
• Strategic partnership with Orano Med expanded to ten Radio-DARPin programs
• MP0533 Phase 1/2a clinical trial showing improved response rates
• Total revenues of CHF 5.0 million in 2024 (down from CHF 7.0 million in 2023)
• Net loss of CHF 54.0 million (improved from CHF 62.0 million in 2023)
• Operating expenses of CHF 66.2 million (reduced from CHF 68.1 million in 2023)

The company raised approximately $20 million in October 2024 from investors including HBM Partners, focusing on radiopharmaceutical pipeline development.

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing DARPin therapeutics, has announced its participation in key investor conferences and its upcoming financial results presentation.

The company will participate in two major healthcare conferences: the TD Cowen 44th Annual Health Care Conference in Boston (March 3-5, 2025) and the Leerink Partners Global Healthcare Conference 2025 in Miami (March 10-12, 2025). CEO Patrick Amstutz and CMO Dr. Philippe Legenne will conduct fireside chats at both events.

The company will host its Full Year 2024 Financial Results Conference Call on March 7, 2025, at 8:00 am ET (2:00 pm CET), following the publication of its Annual Report on March 6.

Molecular Partners (NASDAQ: MOLN) has outlined its clinical expansion plans for 2025, highlighting key developments in its Radio-DARPin and Switch-DARPin programs. The company's Radio-DARPin MP0712, targeting DLL3, will enter first-in-human studies in 2025, while Mesothelin has been selected as the second target in their Radio-DARPin pipeline. Both programs are being co-developed with Orano Med, with their partnership now expanded to 10 programs.

The company reported encouraging results from MP0533's clinical trials, with improved response rates in cohort 8 using more frequent dosing. As of December 31, 2024, the company maintains a strong financial position with CHF 149 million in cash and cash equivalents.

The CD3 Switch-DARPin platform has demonstrated proof-of-concept in solid tumors, showing conditional T cell activation and CD2 co-stimulation, with further data expected in Q2 2025. The company plans to submit an IND application for MP0712 in H1 2025.

Molecular Partners (MOLN) and Orano Med have expanded their strategic collaboration in targeted alpha radio-therapies for cancer, increasing their joint programs from four to ten. The partnership combines Molecular Partners' Radio-DARPin Platform with Orano Med's 212Pb supply and development capabilities.

Under the new agreement, Molecular Partners will lead the development of six additional programs with a royalty arrangement. Orano Med has the option to move two of these programs into 50/50 co-development with commercialization rights. The most advanced program, MP0712, a DLL3-targeted radio-DARPin, is expected to begin human trials in 2025.

The initial agreement from January 2024 covered four programs with equally shared costs and profits. Molecular Partners holds commercialization rights for MP0712 and a second mesothelin-targeting program, while Orano Med has rights to programs three and four. Financial terms weren't disclosed, and MOLN maintains its funding guidance into 2027.

Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company specializing in DARPin therapeutics, has announced its participation in two major investor conferences in January. Chief Operating Officer Alexander Zürcher will present at the Baader Helvea Swiss Equities Conference on January 8 in Bad Ragaz, Switzerland. Subsequently, CEO Patrick Amstutz will present at the 43rd Annual JP Morgan Healthcare Conference on January 15 at 9:00am PT in San Francisco. The presentations will showcase the company's latest developments and outlook for 2025, with webcasts available on the Molecular Partners website.

Molecular Partners (NASDAQ: MOLN) presented data from two programs at ASH 2024: MP0533 phase 1/2a study and preclinical data on MP0621. The MP0533 study, targeting relapsed/refractory AML or MDS/AML, showed an acceptable safety profile in 37 patients across seven cohorts, with initial antileukemic and pharmacodynamic activity. Despite lower than anticipated drug exposure, four responders were reported. The company is amending the protocol to optimize dosing schedules.

The preclinical data for MP0621, a Switch-DARPin candidate for hematopoietic stem cell transplantation conditioning, demonstrated its intended mechanism of HSC depletion while reducing off-target effects. However, non-human primate data doesn't support its use in AML patients as previously hypothesized. The company is now evaluating MP0621 for partnering opportunities.

Molecular Partners announced data presentations at SITC 2024 for two programs: a novel CD3 Switch-DARPin T cell engager and MP0317. The CD3 Switch-DARPin platform demonstrated preclinical proof-of-concept for conditional T cell activation in solid tumors, specifically in ovarian cancer models. The technology features an 'on/off' switch mechanism that activates only in the presence of defined tumor antigens.

For MP0317, comprehensive biomarker analyses from its completed Phase 1 trial showed successful CD40 activation in tumor microenvironments across various solid tumors. The data revealed increases in dendritic cells, M1 macrophages, and other immune cells, supporting its tumor-localized approach. The company is now discussing potential investigator-initiated combination trials.

Molecular Partners will present data from its MP0533 and MP0621 programs at the upcoming ASH Annual Meeting. The clinical update on the ongoing MP0533 phase 1/2a dose escalation study shows an acceptable safety profile and initial antileukemic and pharmacodynamic activity. The Switch-DARPin MP0621 demonstrates cKit+ cell killing while reducing off-target effects associated with systemic anti-CD47 blockade. The presentations will take place at the San Diego Convention Center on December 8-9, 2024, featuring data on these DARPin therapeutics for treating AML/MDS and stem cell transplantation conditioning.

Molecular Partners (MOLN) reported its Q3 2024 interim results, highlighting progress across its portfolio. The company's Radio-DARPin candidate MP0712 is preparing for clinical entry in 2025. The company strengthened its agreement with Orano Med to co-develop four 212Pb-based Radio-DARPin candidates. Financial outlook remains strong with CHF 143.6 million in cash as of September 30, 2024, funding operations into 2027. The company expects total operating expenses of CHF 65-70 million in 2024. A recent US offering raised approximately USD 20 million through ADS sales at USD 5.49 per share.